- Home
- AGEN vs ANIX Comparison
AGEN vs ANIX Comparison
Compare AGEN & ANIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AGEN
- ANIX
- Stock Information
- Founded
- AGEN 1994
- ANIX 1982
- Country
- AGEN United States
- ANIX United States
- Employees
- AGEN N/A
- ANIX N/A
- Industry
- AGEN Biotechnology: Biological Products (No Diagnostic Substances)
- ANIX Biotechnology: Pharmaceutical Preparations
- Sector
- AGEN Health Care
- ANIX Health Care
- Exchange
- AGEN Nasdaq
- ANIX Nasdaq
- Market Cap
- AGEN 87.7M
- ANIX 95.7M
- IPO Year
- AGEN 2000
- ANIX 1987
- Fundamental
- Price
- AGEN $4.28
- ANIX $2.99
- Analyst Decision
- AGEN Buy
- ANIX Strong Buy
- Analyst Count
- AGEN 2
- ANIX 3
- Target Price
- AGEN $14.50
- ANIX $9.00
- AVG Volume (30 Days)
- AGEN 497.3K
- ANIX 71.9K
- Earning Date
- AGEN 08-11-2025
- ANIX 08-27-2025
- Dividend Yield
- AGEN N/A
- ANIX N/A
- EPS Growth
- AGEN N/A
- ANIX N/A
- EPS
- AGEN N/A
- ANIX N/A
- Revenue
- AGEN $101,706,000.00
- ANIX N/A
- Revenue This Year
- AGEN $26.25
- ANIX N/A
- Revenue Next Year
- AGEN N/A
- ANIX N/A
- P/E Ratio
- AGEN N/A
- ANIX N/A
- Revenue Growth
- AGEN N/A
- ANIX N/A
- 52 Week Low
- AGEN $1.38
- ANIX $2.07
- 52 Week High
- AGEN $7.34
- ANIX $4.20
- Technical
- Relative Strength Index (RSI)
- AGEN 38.46
- ANIX 46.57
- Support Level
- AGEN $4.31
- ANIX $2.93
- Resistance Level
- AGEN $4.70
- ANIX $3.03
- Average True Range (ATR)
- AGEN 0.26
- ANIX 0.10
- MACD
- AGEN -0.01
- ANIX 0.01
- Stochastic Oscillator
- AGEN 17.86
- ANIX 44.44
About AGEN Agenus Inc.
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).
About ANIX Anixa Biosciences Inc.
Anixa Biosciences Inc a cancer-focused biotechnology company, develops vaccines and therapies that are focused on critical unmet needs in oncology. The company is developing both diagnostics and therapeutics to detect cancer early, which is curable, and to treat those afflicted once diagnosed. Its segment includes CAR-T Therapeutics; Cancer Vaccines; Anti-Viral Therapeutics and others.